Hepatocellular Carcinoma
Conditions
Interventions
treatment group:Radiotherapy plus Sintilimab
Control group:Interventional therapy
Sponsors
Cancer Hospital Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.R0 resection of hepatocellular carcinoma (HCC) with a surgical margin 400 ng/mL (3) Tumor >5 cm with incomplete capsule; 4.>=18 and =80g/L,ANC>=1.0×10^9 /L,PLT>=40×10^9 /L. 13.Written informed consent obtained.
Exclusion criteria
Exclusion criteria: 1.Vp3 or Vp4 portal vein tumor thrombus (PVTT) or Vv2/Vv3 inferior vena cava (IVC) tumor thrombus on preoperative imaging. 2.Previous anti-HCC therapies, including but not limited to: targeted therapy (e.g., tyrosine kinase inhibitors), immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors) or systemic chemotherapy; 3.Distant metastasis before randomization. 4.Moderate to severe ascites unresponsive to medical management. 5.History of other malignancies, except: carcinoma in situ,early-stage papillary thyroid cancer or basal cell carcinoma of the skin; 6.Previous radiotherapy involving the abdomen. 7.Significant cardiac, renal, or other major organ dysfunction. 8.Active Autoimmune Disease or Psychiatric Disorders. 9.HIV Infection. 10.Pregnant or breastfeeding women. 11.Currently enrolled in another interventional clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year recurrent free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events;2-year overall survival; | — |
Countries
China
Contacts
Public ContactBo Chen
Cancer Hospital Chinese Academy of Medical Sciences
Outcome results
None listed